Search Results | MSF Science Portal

Journal Article

|

Research

Larsson L, Calderwood CJ, Marambire ET, Held K, Banze D, et al.

2025-04-28 • Clinical Infectious Diseases

BACKGROUND

Studies have demonstrated an inverse log-linear relationship between body mass index (BMI) and tuberculosis incidence. However, a person’s BMI is dyn...

Journal Article

|

Research

Singla R, Khan S, Silsarma A, Chavan V, Mahajan R, et al.

2025-03-13 • Clinical Infectious Diseases

BACKGROUND

Bedaquiline (BDQ) resistance presents a critical challenge in the fight against tuberculosis (TB), particularly multidrug-resistant (MDR) strains. Th...

Journal Article

|

Research

Sinha A, Klebe R, Rekart ML, Alvarez JL, Skrahina A, et al.

2025-02-18 • Clinical Infectious Diseases

BACKGROUND

Only 63% of patients initiating multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment in 2020 were treated successfully. 24-Wee...

Journal Article

|

Research

Khan U, Rich M, Franke M, Lachenal N, Ahmed S, et al.

2024-12-10 • Clinical Infectious Diseases

BACKGROUND

The 2022 WHO guidelines on multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) recommend six months of bedaquiline (Bdq) in the all-oral 9-month shorter regimen ...

Journal Article

|

Letter

Crocker-Buque T, Lachenal N, Narasimooloo C, Abdrasuliev T, Parpieva N, et al.

2024-08-15 • Clinical Infectious Diseases

Journal Article

|

Research

van Griensven J, van Henten S, Kibret A, Kassa M, Beyene H, et al.

2024-07-19 • Clinical Infectious Diseases

Background

People with human immunodeficiency virus (PWH) with recurrent visceral leishmaniasis (VL) could potentially drive Leishmania transmission in areas wi...

Journal Article

|

Review

Hasan T, Medcalf E, Nyang'wa BT, Egizi E, Berry C, et al.

2024-03-20 • Clinical Infectious Diseases

BACKGROUND
Effectiveness, safety, tolerability, and adherence are critical considerations in shifting to shorter tuberculosis (TB) regimens. Novel 6-month oral regimens that include ...

Journal Article

|

Letter

Schomaker M, Kerschberger B, Boulle A

2024-03-20 • Clinical Infectious Diseases

Journal Article

|

Research

Sauer SM, Mitnick CD, Khan UT, Hewison CCH, Bastard M, et al.

2024-01-25 • Clinical Infectious Diseases

BACKGROUND
Quantification of recurrence risk following successful treatment is crucial to evaluating regimens for multidrug- or rifampicin-resistant (MDR/RR) tuberculosis (TB). Howev...

Journal Article

|

Short Report

Lotia Farrukh I, Lachenal N, Adenov MM, Ahmed SM, Algozhin Y, et al.

2024-01-25 • Clinical Infectious Diseases

Among 43 pregnant women receiving multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment with bedaquiline and/or delamanid, 98% had favorable treatment outcomes. Of ...

Journal Article

|

Case Report/Series

van Griensven J, van Henten S, Kibret A, Kassa M, Beyene H, et al.

2024-01-09 • Clinical Infectious Diseases

BACKGROUND
HIV patients with recurrent visceral leishmaniasis (VL) could potentially drive Leishmania transmission in areas with anthroponotic transmission such as East-Africa, but s...

Journal Article

|

Research

Hasan T, Medcalf E, Nyang'wa BT, Egizi E, Berry C, et al.

2023-10-24 • Clinical Infectious Diseases

BACKGROUND
Effectiveness, safety, tolerability and adherence are critical considerations in shifting to shorter tuberculosis (TB) regimens. Novel six-month oral regimens that include...

Journal Article

|

Letter

Schomaker M, Kerschberger B, Boulle AM

2023-08-05 • Clinical Infectious Diseases

Journal Article

|

Research

Bonnet MMB, Gabillard D, Domoua SK, Muzoora C, Messou E, et al.

2023-03-08 • Clinical Infectious Diseases

BACKGROUND
In people with HIV (PWH), the WHO-recommended tuberculosis four-symptom screen (W4SS) targeting those who need molecular rapid test may be suboptimal. We assessed the perf...

Journal Article

|

Research

Huerga H, Khan UT, Bastard M, Mitnick CD, Lachenal N, et al.

2022-10-15 • Clinical Infectious Diseases

BACKGROUND
Concomitant use of bedaquiline (Bdq) and delamanid (Dlm) for multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) has raised concerns about a potentially poor risk-ben...

Journal Article

|

Research

Burza S, Mahajan R, Kazmi S, Alexander N, Kumar D, et al.

2022-10-15 • Clinical Infectious Diseases

BACKGROUND
Visceral leishmaniasis (VL) in patients living with Human-Immunodeficiency-Virus (HIV) present an increasingly important patient cohort in areas where both infections are ...

Journal Article

|

Research

Musa AM, Mbui J, Mohammed R, Olobo J, Ritmeijer KKD, et al.

2022-09-27 • Clinical Infectious Diseases

BACKGROUND
This study aimed to determine whether paromomycin plus miltefosine (PM/MF) is noninferior to sodium stibogluconate plus paromomycin (SSG/PM) for treatment of primary visce...

Journal Article

|

Research

Hewison CCH, Khan UT, Bastard M, Lachenal N, Coutisson S, et al.

2022-09-15 • Clinical Infectious Diseases

RATIONALE
Safety of treatment for multidrug-resistant tuberculosis (MDR/RR-TB) can be an obstacle to treatment completion.

OBJECTIVES
Evaluate safety of longer MDR/RR-TB...

Journal Article

|

Commentary

Burry J, Casas CP, Ford NP

2022-08-29 • Clinical Infectious Diseases

Cryptococcal meningitis accounts for 1 in 5 AIDS-related deaths globally. World Health Organization guidelines strongly recommend a single high dose of liposomal amphotericin B as part o...

Journal Article

|

Letter

Brooks HM, Jean Paul MK, Claude KM, Houston S, Hawkes MT

2017-08-01 • Clinical Infectious Diseases

Science Portal

Body mass index trajectories and association with tuberculosis risk in a cohort of household contacts in Southern Africa

Bedaquiline resistance and treatment outcomes among patients with tuberculosis previously exposed to bedaquiline in India: A multicentric retrospective cohort study

The effectiveness and safety of bedaquiline, pretomanid, and linezolid (BPaL)-based regimens for rifampicin-resistant tuberculosis in non-trial settings - A prospective cohort study in Belarus and Uzbekistan

The frequency and incidence of QT prolongation with extended use of bedaquiline or delamanid in a large, multi-country MDR/RR-TB cohort

Pregnancy outcomes in multidrug-resistant tuberculosis in TB-PRACTECAL

Chronic high-level parasitemia in HIV-infected individuals with or without visceral leishmaniasis in an endemic area in Northwest Ethiopia: Potential superspreaders?

The safety and tolerability of linezolid in novel short-course regimens containing bedaquiline, pretomanid, and linezolid to treat rifampicin-resistant tuberculosis: An individual patient data meta-analysis

Is same-day antiretroviral therapy initiation beneficial? Methodological aspects when comparing observational and randomized studies

Estimating post-treatment recurrence after multidrug-resistant tuberculosis treatment among patients with and without HIV: the impact of assumptions about death and missing follow-up

Pregnancy and birth outcomes in patients with multidrug-resistant tuberculosis treated with regimens that include new and repurposed drugs

Chronic high level parasitemia in HIV-infected individuals with or without visceral leishmaniasis in an endemic area in North-West Ethiopia: potential superspreaders?

The safety and tolerability of linezolid in novel short-course regimens containing bedaquiline, pretomanid and linezolid to treat rifampicin-resistant tuberculosis: an individual patient data meta-analysis

Response to “treatment outcomes after offering same-day Initiation of human immunodeficiency virus (HIV) treatment—how to interpret discrepancies between different studies”

High performance of systematic combined urine LAM test and sputum Xpert MTB/RIF® for tuberculosis screening in severely immunosuppressed ambulatory adults with HIV

Safety and effectiveness outcomes from a 14-country cohort of patients with multi-drug resistant tuberculosis treated concomitantly with bedaquiline, delamanid and other second-line drugs

AmBisome monotherapy and combination AmBisome - miltefosine therapy for the treatment of visceral leishmaniasis in patients co-infected with HIV in India: a randomised open label, parallel arm, phase 3 trial

Paromomycin and miltefosine combination as an alternative to treat patients with visceral leishmaniasis in Eastern Africa: A randomized, controlled, multicountry trial

Safety of treatment regimens containing bedaquiline and delamanid in the endTB cohort

Access to medicines for treating people With cryptococcal meningitis

Malaria in an Internally Displaced Persons Camp in the Democratic Republic of the Congo